On September 26, 2023 SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology, and its U.S. R&D subsidiary, Proteovant Therapeutics, reported that they will present data on the discovery and characterization of a selective IKZF2 molecular glue degrader with best-in-class potential, and on MOPED, a novel platform for the discovery of molecular glues, at the 20th Annual Discovery on Target Conference being held in Boston, September 25-28, 2023 (Press release, SK biopharmaceuticals, SEP 26, 2023, https://www.prnewswire.com/news-releases/sk-biopharmaceuticals-proteovant-therapeutics-presents-preclinical-data-on-ikzf2-protein-degrader-program-and-moped-molecular-glue-screening-platform-at-the-20th-annual-discovery-on-target-conference-301938441.html [SID1234635422]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These presentations are the first in a series in which the companies will unveil exciting results from its targeted protein degradation (TPD) studies and MOPEDTM Molecular Glue Screening Platform. TPD harnesses the body’s natural protein disposal system and offers the potential to develop new medicines targeting historically difficult-to-drug proteins that play an important role in causing serious diseases. SK Biopharmaceuticals and Proteovant Therapeutics are discovering and developing potential best-in-class and first-in-class degraders to engage previously undruggable targets.
"We are excited to share new data on our IKZF2 molecular glue degrader that demonstrates the potential to combine with immune checkpoint therapies for the treatment of cancer," said Donghoon Lee, President and CEO of SK Biopharmaceuticals and SK Life Science. "We are also pleased to present data showing how our MOPED platform can help find molecular glues with the potential to destroy malfunctioning proteins and kill cancer cells or inhibit their growth."
Discovery on Target Meeting Presentations:
Title: MOPED: A Novel Platform for the Discovery of Molecular Glues
Presenter: Corey Strickland, Ph.D.
Date/Time: Wednesday, September 27; 9:30 – 10:00 AM
Title: Discovery and Characterization of an IKZF2 Selective Molecular Glue Degrader with Best-in-Class Potential
Presenter: Courtney G. Havens, Ph.D.
Date/Time: Thursday, September 28; 2:50 – 3:20 PM